Fig. 1From: Mutational status predicts the risk of thromboembolic events in lung adenocarcinomaEvent-free survival of patients in the Epidermal Growth Factor Receptor (EGFR), anaplastic lymphoma kinase (ALK) mutated groups and in the unexposed group. Calculated with the same Cox regression model as used in Table 3. Demonstrates the difference in event-free survival between the unexposed and mutated groups. Cumulative event-free survival variable: time before the first thromboembolic eventBack to article page